Clinical Trial Update: Study for Adolescents and Adults With Ornithine Transcarbamylase Deficiency to Evaluate Safety and Tolerability of ARCT-810 [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating ARCT-810 for Ornithine transcarbamylase deficiency has been terminated, representing a status update on the trial in adolescents and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ornithine Transcarbamylase Deficiency

Drugs mentioned

• ARCT-810

Snippet

Sponsor: Arcturus Therapeutics, Inc. | Conditions: Ornithine Transcarbamylase Deficiency, OTC Deficiency | Phase 2 | Status: TERMINATED